|
A) Multivariable model including QoL at last available follow-up
|
|
QoL at last available follow-up a
|
1.12
|
1.06; 1.18
|
< 0.001
|
0.91
|
0.87; 0.96
|
0.001
|
1.14
|
1.08; 1.20
|
< 0.001
|
0.83
|
0.69; 0.99
|
0.048
|
|
Age a
|
1.32
|
1.14; 1.54
|
< 0.001
|
1.30
|
1.12; 1.51
|
0.001
|
1.27
|
1.09; 1.48
|
0.002
|
1.25
|
1.07; 1.46
|
0.006
|
|
Number of comorbidities
|
|
0
|
1.00
| | |
1.00
| | |
1.00
| | |
1.00
| | |
|
1
|
2.40
|
1.15; 5.01
|
0.02
|
1.93
|
0.98; 3.77
|
0.057
|
2.51
|
0.92; 6.81
|
0.071
|
2.03
|
0.93; 4.41
|
0.075
|
|
2
|
2.10
|
1.02; 4.32
|
0.043
|
1.62
|
0.83; 3.19
|
0.161
|
2.40
|
0.90; 6.40
|
0.079
|
2.24
|
1.05; 4.80
|
0.038
|
|
3
|
2.78
|
1.26; 6.09
|
0.011
|
2.15
|
1.02; 4.53
|
0.043
|
3.16
|
0.99; 10.05
|
0.052
|
2.31
|
0.97; 5.46
|
0.057
|
|
4+
|
1.95
|
0.69; 5.49
|
0.205
|
1.98
|
0.77; 5.07
|
0.155
|
1.30
|
0.29; 5.86
|
0.734
|
2.80
|
1.00; 7.86
|
0.051
|
|
Change in FVC % predicted
|
|
Stable/increase
|
1.00
| | |
1.00
| | |
1.00
| | |
1.00
| | |
|
Decrease by 0 to 10%
|
1.63
|
0.98; 2.71
|
0.058
|
1.60
|
0.97; 2.64
|
0.066
|
1.41
|
0.75; 2.64
|
0.286
|
1.75
|
1.01; 3.03
|
0.047
|
|
Decrease by > 10%
|
2.34
|
1.18; 4.62
|
0.015
|
2.29
|
1.16; 4.51
|
0.017
|
2.14
|
0.87; 5.26
|
0.096
|
2.70
|
1.32; 5.53
|
0.007
|
|
Hospitalisation
|
1.26
|
0.80; 1.97
|
0.322
|
1.54
|
0.98; 2.40
|
0.06
|
1.00
|
0.57; 1.74
|
0.994
|
1.29
|
0.81; 2.06
|
0.286
|
|
Overall physician’s judgement of clinical course of IPF
|
|
Stable disease
|
1.00
| | |
1.00
| | |
1.00
| | |
1.00
| | |
|
Slow progression
|
1.48
|
0.92; 2.38
|
0.106
|
1.70
|
1.08; 2.69
|
0.022
|
1.30
|
0.71; 2.37
|
0.399
|
1.91
|
1.16; 3.17
|
0.012
|
|
Rapid progression
|
0.97
|
0.46; 2.04
|
0.933
|
1.18
|
0.55; 2.53
|
0.674
|
1.06
|
0.46; 2.42
|
0.896
|
1.25
|
0.53; 2.95
|
0.617
|
|
No judgement possible
|
0.89
|
0.46; 1.74
|
0.743
|
0.98
|
0.52; 1.84
|
0.95
|
1.26
|
0.54; 2.93
|
0.588
|
0.94
|
0.47; 1.91
|
0.871
|
|
B) Multivariable model including change in QoL between baseline and last available follow-up
|
|
Change in QoL between baseline and last available follow-up a
|
1.05
|
0.98; 1.13
|
0.148
|
0.97
|
0.91; 1.04
|
0.364
|
1.07
|
0.98; 1.16
|
0.127
|
0.85
|
0.68; 1.07
|
0.165
|
|
Age a
|
1.30
|
1.11; 1.52
|
0.001
|
1.31
|
1.12; 1.53
|
0.001
|
1.26
|
1.02; 1.56
|
0.031
|
1.26
|
1.07; 1.48
|
0.006
|
|
Number of comorbidities
|
|
0
|
1.00
| | |
1.00
| | |
1.00
| | |
1.00
| | |
|
1
|
1.98
|
0.97; 4.04
|
0.061
|
1.83
|
0.92; 3.63
|
0.084
|
2.03
|
0.71; 5.84
|
0.187
|
1.93
|
0.89; 4.20
|
0.096
|
|
2
|
1.85
|
0.90; 3.79
|
0.092
|
1.70
|
0.85; 3.40
|
0.135
|
2.01
|
0.65; 6.21
|
0.226
|
2.14
|
0.99; 4.63
|
0.054
|
|
3
|
2.40
|
1.10; 5.24
|
0.028
|
2.25
|
1.06; 4.76
|
0.035
|
3.68
|
1.17; 11.55
|
0.026
|
2.18
|
0.91; 5.23
|
0.082
|
|
4+
|
2.04
|
0.75; 5.57
|
0.165
|
2.27
|
0.87; 5.92
|
0.093
|
1.54
|
0.26; 9.06
|
0.634
|
2.99
|
1.09; 8.22
|
0.034
|
|
Change in FVC % predicted
|
|
Stable/increase
|
1.00
| | |
1.00
| | |
1.00
| | |
1.00
| | |
|
Decrease by 0 to 10%
|
1.69
|
1.02; 2.82
|
0.044
|
1.65
|
0.99; 2.76
|
0.055
|
1.11
|
0.57; 2.14
|
0.762
|
1.67
|
0.95; 2.91
|
0.073
|
|
Decrease by > 10%
|
2.16
|
1.08; 4.31
|
0.029
|
2.26
|
1.14; 4.50
|
0.02
|
1.72
|
0.71; 4.14
|
0.227
|
2.43
|
1.18; 5.00
|
0.015
|
|
Hospitalisation
|
1.35
|
0.85; 2.13
|
0.202
|
1.54
|
0.98; 2.42
|
0.059
|
1.30
|
0.68; 2.45
|
0.427
|
1.30
|
0.81; 2.08
|
0.285
|
|
Overall physician’s judgement of clinical course of IPF
|
|
Stable disease
|
1.00
| | |
1.00
| | |
1.00
| | |
1.00
| | |
|
Slow progression
|
1.69
|
1.05; 2.73
|
0.03
|
1.83
|
1.14; 2.94
|
0.012
|
1.38
|
0.67; 2.85
|
0.381
|
1.89
|
1.15; 3.12
|
0.013
|
|
Rapid progression
|
1.42
|
0.69; 2.91
|
0.341
|
1.63
|
0.76; 3.46
|
0.207
|
1.27
|
0.47; 3.41
|
0.636
|
1.38
|
0.61; 3.12
|
0.439
|
|
No judgement possible
|
0.97
|
0.49; 1.92
|
0.922
|
0.96
|
0.50; 1.83
|
0.902
|
1.24
|
0.52; 2.95
|
0.622
|
0.83
|
0.39; 1.77
|
0.635
|
